Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | HSPH1 | Q92598 | 1/20 | 0.51 |
| ▸ | MTTP | P55157 | 10/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | APOB | P04114 | 2/20 | 0.46 |
| ▸ | KLRK1 | P26718 | 3/20 | 0.46 |
| ▸ | MICA | Q29983 | 3/20 | 0.46 |
| ▸ | RAET1L | Q5VY80 | 3/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL399742 | 0.95 | MTTP (0.49) | PPARAPPARGNR1H4PPARDHSPH1 | |
| SCHEMBL402136 | 0.91 | MTTP (0.48) | PPARAPPARGNR1H4PPARDHSPH1 | |
| SCHEMBL2597850 | 0.91 | PPARG (0.53) | PPARAPPARGNR1H4PPARDMTTP | |
| SCHEMBL403325 | 0.90 | MTTP (0.47) | PPARAPPARGNR1H4PPARDHSPH1 | |
| SCHEMBL401790 | 0.89 | MTTP (0.47) | PPARAPPARGNR1H4PPARDHSPH1 | |
| SCHEMBL402135 | 0.88 | MTTP (0.51) | MTTPAPOBKLRK1MICARAET1L | |
| SCHEMBL13580512 | 0.85 | MTTP (0.50) | PPARAPPARGNR1H4PPARDMTTP | |
| SCHEMBL401451 | 0.84 | MTTP (0.47) | MTTPAPOBKLRK1MICARAET1L | |
| SCHEMBL14031471 | 0.84 | KLRK1 (0.52) | MTTPAPOBKLRK1MICARAET1L | |
| SCHEMBL402457 | 0.84 | MTTP (0.48) | PPARAPPARGNR1H4PPARDMTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101774-B2 | Ester derivatives and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2012-01-24 | — | — | US | disclosed |
| EP-1803452-A1 | ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-20060089392-A1 | Ester derivatives and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089392-A1 | Ester derivatives and medicinal use thereof | MTTP, CETP, LIPA | PPARA 119/4885PPARG 322/4885NR1H4 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.